Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). This approval supports the use of Signatera for patients with colorectal cancer (CRC) in the adjuvant setting…
Atlanta Gastroenterology Associates has agreed to pay $4.75 million to settle allegations that it violated the False Claims Act by…
The U.S. healthcare system is approaching a tipping point, driven by three converging threats: rising care costs, a growing chronic…
In a bid to close persistent colorectal cancer (CRC) screening gaps, Guardant Health has launched a community grant program offering…
The 2025 Identity Theft Resource Center report confirms what many physician-owners are feeling: cyberattacks are no longer random — they’re…
DDW 2026
Several studies presented at DDW 2026 highlighted emerging approaches that could reshape…
A structured triage system for interventional GI referrals changed the originally requested…
Headlines in GI
Two gastroenterology organizations have disclosed phishing-related data breaches that exposed sensitive patient…
Thought Leadership
Roughly half of patients with an abnormal stool-based colorectal cancer screening result…
Why Trust, Access, and Relationships Drive GI Growth By Dr. Charles Accurso…
The microbiome has become one of the biggest battlegrounds in modern medicine.…